July 21, 2016.
A team of researchers from the National Institute of Health and Medical Research (Inserm) has reportedly developed an antibody capable of effectively fighting multiple sclerosis, this autoimmune disease, which affects the brain and spinal cord .
Block the progression of motor disorders
Inserm researchers, working under the leadership of Professor Denis Vivien, have developed an antibody with potential therapeutic effects against multiple sclerosis. A major discovery which represents real hope for patients suffering from this disease, which causes motor, sensory and cognitive disorders and which can lead to total paralysis.
According to the researchers, immune cells in patients with multiple sclerosis destroy the myelin sheath that surrounds and protects extensions of neurons. A destruction which then disrupts the transmission of nerve impulses. So they developed an antibody, called Glunomab, which restricts the passage of aggressive cells of the immune system into the nervous system.
No side effects were found
” This drug has shown high efficiency in mice, a mouse with something resembling multiple sclerosis », Explains Fabien Docagne, researcher at Inserm. ” When this drug is given, the mouse gets better. Disease progression is prevented and mice do not have hindquarters. “
After an intravenous injection of Glunomab, the progression of motor disorders is blocked and no side effects have yet been observed. ” Under these conditions, given its effectiveness, it is hoped that one day this target could become a treatment in humans. », Added the researcher. Inserm is therefore looking for funding – several million euros – to launch a first clinical trial in humans.
Read also: Multiple sclerosis: a lesson in courage
